Assembly Biosciences expands ABI-6250 into PBC and PSC; Phase 2 basket study planned Q1 2027

ASSEMBLY BIOSCIENCES, INC.

ABI-6250, oral NTCP inhibitor, to be studied in PBC and PSC basket Phase 2 starting Q1 2027.
Phase 1a completed; data show dose-dependent bile acid elevations confirming target engagement.
Chronic tox studies support longer-term dosing; Phase 2 in HDV remains on track for Q4 2026.
Pre-IND FDA meeting constructive; company views feedback as helpful for advancement.
PSC has no approved therapies; PBC has significant unmet need despite existing treatments.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.